Invention Grant
- Patent Title: Peptide inhibition of CCR3-mediated diseases or conditions
-
Application No.: US15639434Application Date: 2017-06-30
-
Publication No.: US10363286B2Publication Date: 2019-07-30
- Inventor: Steven Jules Ackerman , Fan Gao Laffey , Ben Hitchinson , Boris Garnier , Vadim Gaponenko , Nadya Tarasova , Hazem Abdelkarim
- Applicant: The Board of Trustees of the University of Illinois , The United States of America, as Represented by the Secretary, Dept. of Health and Human Services
- Applicant Address: US IL Urbana US DC Washington
- Assignee: The Board of Trustees of the University of Illinois,The United States of America, as represented by the Secretary, Department of Health and Human Services
- Current Assignee: The Board of Trustees of the University of Illinois,The United States of America, as represented by the Secretary, Department of Health and Human Services
- Current Assignee Address: US IL Urbana US DC Washington
- Agency: Licata & Tyrrell P.C.
- Main IPC: A61K38/19
- IPC: A61K38/19 ; A61K47/10 ; A61K47/68 ; A61P11/06 ; A61P37/08 ; C07K14/52 ; C07K14/715 ; A61K38/00 ; C07K14/47 ; A61K9/00
Abstract:
A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.
Public/Granted literature
- US20170304401A1 PEPTIDE INHIBITION OF CCR3-MEDIATED DISEASES OR CONDITIONS Public/Granted day:2017-10-26
Information query
IPC分类:
